Release date: 2015-08-25 Recently, many biotechnology companies have gained a lot in the development of gene therapy, then you may have noticed a trend: many eye-catching biological upstarts, whose core technology is licensed from ReGenX Bio. Now the behind-the-scenes pusher decided to go to the front: the company will raise $100 million through IPO to develop its own gene therapy, which is at the forefront of the industry. ReGenXBio was founded by gene therapy pioneer James Wilson and plans to land on NASDAQ under the code "RGNX". The management has not yet specified the specific stock share, intent price and which bank is ready to subscribe. ReGenXBio plans to use the funds raised by the IPO to promote the development of several pre-clinical gene therapies: homozygous familial hypercholesterolemia, a rare genetic disorder that causes high-risk cholesterol. Treatment of early stage research of Hurler Syndrome, which is a rare disease that can cause cognitive impairment; preclinical treatment of wet age-related macular degeneration, which is the most common form of blindness one of the reasons. ReGenXBio will use its proprietary NAV technology to support each development candidate, using adeno-associated viruses (AAV) to transmit functional genes that can replace or break down disease-causing erroneous genes. The company has signed 8 NAV projects and its scale has attracted much attention. Managers believe that current projects will enrich the company's technology and pave the way for patent research and development. ReGenX completed approximately $70.5 million in Series D financing in May, with investors VivoCapital, Venrock and Brookside Capital, which in January had raised $30 million in C-round financing. At the same time, in this summer, the momentum of biotechnology in Wall Street has not diminished. In the past few weeks, Global Blood Therapeutics, Aimmune Therapeutics and Zynerba Pharmaceuticals have successfully carried out IPOs, and the company's echelon that wants to go public is increasingly growing. Large, including Adynxx, Gensight Biologics and Edge Therapeutics. The potential of biotechnology has made many investors yearn for the future, and the amount of investment has skyrocketed. Even the behind-the-scenes ReGenX Bio wants to jump out and share a piece of it. It is enough to see that the competition among pharmaceutical companies has become increasingly hot and more demanding. The company's core technology is excellent enough to get a good return from a huge investment. Source: Health Bang Dishwash Liquid,Dish Washing Soap,Dish Washer Detergent,Kitchen Dishwashing Liquid Detergent Wuxi Keni Daily Cosmetics Co.,Ltd , https://www.kenidailycosmetics.com